Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072434 · ClinicalTrials.gov registry record · Phase 3
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,199
- Enrollment target
NCT02072434 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 2,199 participants.
The verdict
NCT02072434, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,199 participants
- Enrollment target
Study Summary
The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join. Their doctors must plan to use shock to make their hearts beat normally. About 2200 people from different countries will join. They will have an equal chance of receiving either treatment. They are anticipated to be in the study for around 82 days. Tests will include physicals and finger-pricks. Participants will provide blood and urine samples.
Interventions
- DRUG Enoxaparin
- DRUG Warfarin
- DRUG Edoxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,199 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2016-02-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072434
The ClinicalTrials.gov registry entry for NCT02072434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enoxaparin is the first listed.
NCT02072434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072434 about?
NCT02072434 is a clinical study titled "Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)". The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join. Their doctors must plan...
What is the current status of trial NCT02072434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,199 participants. The study started on 2014-03-25. Estimated completion is 2016-02-03.
What interventions are being tested in trial NCT02072434?
The interventions under investigation include: Enoxaparin (DRUG), Warfarin (DRUG), Edoxaban (DRUG).
Who is sponsoring clinical trial NCT02072434?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.